IGKV1D-22 and cancer: Importantly, earlier generations of S100A8/A9 blockers including laquinimod (ABR-215062), tasquinimod (ABR-215050) and paquinimod (ABR-215757), have been or are currently undergoing clinical testing for treatment of inflammatory diseases and cancer [57].